Role of “old” pharmacological agents in the treatment of Cushing’s syndrome

A. G. Ambrogio, F. Cavagnini

Research output: Contribution to journalReview articlepeer-review


Despite recent advances in the management of endogenous Cushing’s syndrome (CS), its treatment remains a challenge. When surgery has been unsuccessful or unfeasible as well in case of recurrence, the “old” pharmacological agents represent an important alternative for both ACTH-dependent and independent hypercortisolism. Especially in the latter, the advent of novel molecules directly targeting ACTH secretion has not outweighed the “old” drugs, which continue to be largely employed and have recently undergone a reappraisal. This review provides a survey of the “old” pharmacological agents in the treatment of CS.

Original languageEnglish
Pages (from-to)957-965
Number of pages9
JournalJournal of Endocrinological Investigation
Issue number9
Publication statusPublished - Sep 1 2016


  • Adrenal blocking agents
  • Cabergoline
  • Cushing’s disease
  • Cushing’s syndrome
  • Efficacy
  • Medical therapy
  • Mifepristone
  • Pasireotide
  • Side effects

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Role of “old” pharmacological agents in the treatment of Cushing’s syndrome'. Together they form a unique fingerprint.

Cite this